Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 246 | 42 | 200 |
| Samples | 235 | 37 | 194 |
| Peptides | 134 | 27 | 110 |
Function
PCBP1 · Poly(rC) binding protein 1
This intronless gene is thought to have been generated by retrotransposition of a fully processed PCBP-2 mRNA. This gene and PCBP-2 have paralogues (PCBP3 and PCBP4) which are thought to have arisen as a result of duplication events of entire genes. The protein encoded by this gene appears to be multifunctional. It along with PCBP-2 and hnRNPK corresponds to the major cellular poly(rC)-binding protein. It contains three K-homologous (KH) domains which may be involved in RNA binding. This encoded protein together with PCBP-2 also functions as translational coactivators of poliovirus RNA via a sequence-specific interaction with stem-loop IV of the IRES and promote poliovirus RNA replication by binding to its 5'-terminal cloverleaf structure. It has also been implicated in translational control of the 15-lipoxygenase mRNA, human Papillomavirus type 16 L2 mRNA, and hepatitis A virus RNA. The encoded protein is also suggested to play a part in formation of a sequence-specific alpha-globin mRNP complex which is associated with alpha-globin mRNA stability. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000303577 | Q15365 | 246 | 134 |
Gene Properties
Recurrent Mutations
All 134 amino-acid changes on canonical ENST00000303577 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PCBP1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PCBP1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 7/40 18% | 0/0 0% |
| Burkitts Lymphoma | 5/32 16% | 9/196 5% |
| Colorectal Carcinoma | 3/143 2% | 84/3239 3% |
| Hodgkins Lymphoma | 2/16 12% | 1/122 1% |
| Bladder Carcinoma | 3/58 5% | 16/956 2% |
| Osteosarcoma | 0/45 0% | 2/166 1% |
| Endometrial Carcinoma | 1/42 2% | 5/612 1% |
| Non-Cancerous | 0/104 0% | 7/830 1% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 7/1390 0% |
| Gastric Carcinoma | 2/74 3% | 8/1809 0% |
| B-Cell Non-Hodgkins Lymphoma | 5/88 6% | 8/2534 0% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Hepatocellular Carcinoma | 3/46 7% | 7/2210 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Esophageal Carcinoma | 0/23 0% | 3/769 0% |
| Plasma Cell Myeloma | 1/44 2% | 0/305 0% |
| Pancreatic Carcinoma | 0/89 0% | 4/1611 0% |
| Other Solid Cancers | 0/94 0% | 3/1515 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 5/2550 0% |
| Melanoma | 0/210 0% | 4/1899 0% |
| Ovarian Carcinoma | 0/109 0% | 2/998 0% |
| Head and Neck Carcinoma | 0/85 0% | 3/1574 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 3/1592 0% |
| Breast Carcinoma | 1/144 1% | 5/3264 0% |
| Glioma | 0/52 0% | 3/2127 0% |
| Other Sarcomas | 0/69 0% | 1/699 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 1/810 0% |
| Biliary Tract Carcinoma | 0/54 0% | 1/950 0% |
| Kidney Carcinoma | 0/85 0% | 2/1862 0% |
| Other Blood Cancers | 1/61 2% | 1/2725 0% |
Mutation Distribution
Where PCBP1 is mutated · all tissues, split by cell line vs tissue
How many mutations in PCBP1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 246 mutations in PCBP1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|